EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 October 2013
EMA/CHMP/648055/2013
Committee for Medicinal Products for Human Use (CHMP)

**Summary of opinion[1] (post authorisation)**

# Pandemic Influenza Vaccine H5N1 Baxter

pandemic influenza vaccine (whole virion, Vero cell derived, inactivated)

On 24 October 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Pandemic Influenza Vaccine H5N1 Baxter. The marketing authorisation holder for this medicinal product is Baxter AG. They may request a re-examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The CHMP adopted a new indication to include children and adolescents from the age of 6 months onwards. For information, the full indication for Pandemic Influenza Vaccine H5N1 Baxter will be as follows:

"Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance."

Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.



[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued within 44 days (Type II variations) and 67 days (Annex II applications) from adoption of the opinion.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8613
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union